Compare DexCom, Inc. (DXCM) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.66 (market cap $7.77B). The key difference: DexCom, Inc. is far larger — about 4.1× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| DXCM | PDBC | |
|---|---|---|
Market Cap | $31.86B | $7.77B |
Volume | 3,607,070 | 6,100,303 |
Sector | Health | — |
52-Week High | $92.34 | $20.10 |
52-Week Low | $54.84 | $13.16 |
Typical Hold Time | 62 Days | 56 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.65, up 1.24% with a bullish technical signal from moving averages. The fund has delivered strong performance, rising 45.66% year-to-date through Q3 2026, driven by energy and agricultural commodity gains amid geopolitical tensions. Institutional interest is growing with multiple firms increasing positions, though short interest surged 215.4% in September, indicating some bearish sentiment.
The outlook remains positive given ongoing commodity strength and defensive positioning, but risks include geopolitical volatility and potential commodity price corrections. The fund offers exposure to broad commodities as investors shift away from concentrated tech sectors, though elevated short interest suggests near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
